



JAGSONPAL

JAGSONPAL PHARMACEUTICALS LIMITED

Regd. office : T-210 J, Shahpur Jat, New Delhi-110 049 (INDIA)

Fax : 0091-11-26498341,26494708, Phone: 0091-11-26494519-24

E-mail: admin@jagsonpal.com

Audited Financial Results for the Quarter/Year ended 31.03.2012

Particulars	Rs. in lacs				
	3 months ended 31.03.2012	Preceding 3 months ended 31.12.2011	Corresponding 3 months ended 31.03.2011	12 Months Ended 31.03.2012	12 Months Ended 31.03.2011
	Audited	UnAudited	Audited	Audited	Audited
1 Income from operations					
a Net sales/Income from Operations (Net of excise duty)	4146.19	4659.67	3185.53	17651.39	16095.50
b Other Operating Income					
Total Income from operations (net)	4146.19	4659.67	3185.53	17651.39	16095.50
2 Expenses					
a Cost of materials consumed	700.32	2806.38	2227.48	7955.91	7379.61
b Purchases of stock-in-trade	875.69	260.31	25.06	1572.28	727.95
c. Changes in inventories of finished goods, work in progress and Stock in trade	337.83	-859.90	-643.34	-1073.60	192.46
d. Employee benefits expenses	905.61	966.89	749.91	3650.73	3222.48
e. Depreciation and amortisation expense	58.00	75.50	53.64	253.58	220.09
f. Other expenses	968.12	1009.28	672.01	3884.60	3119.94
Total expenses	3845.57	4258.46	3084.76	16243.50	14862.53
3 Profit from Operations before Other Income, Finance Cost and Exceptional items (1-2)	300.62	401.21	100.77	1407.89	1232.97
4 Other Income	11.57	19.34	26.02	36.92	26.02
5 Profit from ordinary activities before finance cost and Exceptional items (3+4)	312.19	420.55	126.79	1444.81	1258.99
6 Finance Cost	153.08	103.09	50.72	435.82	332.18
7 Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	159.11	317.46	76.07	1008.99	926.81
8 Exceptional Items					
Profit(+)/Loss(-) from Ordinary Activities before tax (7+8)	159.11	317.46	76.07	1008.99	926.81
10 Tax expense	65.08	85.23	36.85	263.31	208.85
11 Net Profit/Loss(-) from Ordinary Activities after tax (9-10)	94.03	232.23	39.22	745.68	717.96
12 Extraordinary Items (net of tax expense Rs. lacs)					
13 Net Profit(+)/Loss(-) for the period(11-12)	94.03	232.23	39.22	745.68	717.96
14 Share of profit/(Loss) of associates					
15 Minority interest					
16 Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of associates (13-14-15)	94.03	232.23	39.22	745.68	717.96
17 Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90	1309.90
18 Reserves excluding Revaluation reserves as per Balance sheet of pr. Accounting yr				7208.47	6615.03
19.i Earnings Per Share (before extraordinary items)					
a. Basic (Rs.)	0.35	0.89	0.15	2.84	2.74
b. Diluted (Rs.)	0.35	0.89	0.15	2.84	2.74
19.ii Earnings Per Share (after extraordinary items)					
a. Basic (Rs.)	0.35	0.89	0.15	2.84	2.74
b. Diluted (Rs.)	0.35	0.89	0.15	2.84	2.74



Factory : 20 K.M. Mathura Road, Post Office, Faridabad-121003 (India) Phone:0091-95129-2275952, 2275953
 Factory : Plot No. 14, 15, 16, 55, 56, 57, Sector-5, IIE, Pant Nagar, Rudrapur (U.S. Nagar)-263153 Uttara Khand



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. office : T-210 J, Shahpur Jat, New Delhi-110 049 (INDIA)

Fax : 0091-11-26498341,26494708, Phone: 0091-11-26494519-24

E-mail: admin@jagsonpal.com

Audited Financial Results for the Quarter/Year ended 31.03.2012

Particulars	Rs. in lacs				
	3 months ended 31.03.2012	Preceding 3 months ended 31.12.2011	Corresponding 3 months ended 31.03.2011	12 Months Ended 31.03.2012	12 Months Ended 31.03.2011
	Audited	UnAudited	Audited	Audited	Audited
INVESTOR COMPLAINTS					
Pending at the beginning of the quarter	0				
Received during the quarter	32				
Disposed of during the quarter	32				
Remaining unresolved at the end of the quarter	0				

Notes

1. The Audited Financial Results for the Quarter ended 31.3.2012 have been reviewed by the Audit Committee. The Board of Directors has approved the financial Results at its meeting held on 30.05.2012
2. The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
3. The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.
4. Previous year figures have been regrouped / rearranged wherever necessary.
5. The Board has recommended a dividend of Rs. 0.50 per equity shares on 2,61,98,000 Equity Shares of Rs. 5/- each for the year 2011-12

By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar
Managing Director



Place : New Delhi

Date : 30.05.2012

Auditor's Report on Quarterly/yearly Financial Results for 31.03.2012 of Jagsonpal
Pharmaceuticals Limited Pursuant to the Clause 41 of the Listing Agreement

To

Board of Directors of Jagsonpal Pharmaceuticals Limited

We have audited the quarterly financial results of Jagsonpal Pharmaceuticals Limited for the quarter ended 31.03.2012 and the year to date results for the period 01.04.2011 to 31.03.2012, attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, issued pursuant to the Companies (Accounting Standards) Rules, 2006 as per section 211(3C) of the Companies Act, 1956 or by the Institute of Chartered Accountants of India and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended 31.03.2012 as well as the year to date results for the period from 01.04.2011 to 31.03.2012.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.



Place: New Delhi
Date: 30th May, 2012

For P.P. Thukral & Company
Chartered Accountants
FRN. 000632N


Suresh Sethi
Partner
M.No. 89318

JAGSONPAL PHARMACEUTICALS LIMITED

Statement of Assets and Liabilities

Rs. In lacs

Rs. In lacs

	As at 31.03.2012	As at 31.03.2011		As at 31.03.2012	As at 31.03.2011
A EQUITY AND LIABILITIES			B ASSETS		
1 Shareholders' funds			1 Non-current assets		
(a) Share Capital	1309.90	1309.90	(a) Fixed Assets	6004.71	5765.28
(b) Reserves and surplus	8537.04	7981.49	(b) Goodwill	3.00	3.00
Sub-total - Shareholders' funds	9846.94	9291.39	(c) Non-current investments	0.05	0.05
2 Non-current liabilities			(d) Long term loans and advance	509.14	318.88
(a) Long term borrowings	27.03	26.32	Sub-total - Non-current assets	6516.90	6087.22
(b) Deferred tax liabilities (net)	398.27	336.77			
Sub-total - Non-current liabilities	425.30	363.09	2 Current assets		
3 Current liabilities			(a) Current investments		
(a) Short term borrowing	3462.32	2833.07	(b) Inventories	3521.61	2255.31
(b) Trade payables	814.11	461.19	(c) Trade receivables	4230.74	4298.47
(c) Other current liabilities	478.74	342.34	(d) Cash and Cash equivalents	988.07	732.57
(d) Short term provisions	582.54	380.74	(e) Short term loans and advance	352.62	298.24
Sub-Total - Current liabilities	5337.71	4017.34	Sub-Total - Current assets	9093.05	7584.59
TOTAL - EQUITY AND LIABILITIES	15609.95	13671.82	TOTAL - ASSETS	15609.95	13671.82

By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar

Rajpal Singh Kochhar
Managing Director

Place : New Delhi
Date : 30.05.2012

